Highlights
- Chimeric has executed a clinical study agreement to support “ADVENT-AML” Phase 1B trial.
- The trial using off-the-shelf universal donor NK cell therapy CHM 0201 would enrol patients with newly diagnosed acute myeloid leukaemia.
- Under the agreement, the company will extend partial financial support.
Shares of Chimeric Therapeutics Limited (ASX:CHM) traded higher by 13.33% to AU$0.034 apiece early morning on 13 September 2023. The share price uptick followed a company update regarding a new clinical study agreement with The University of Texas MD Anderson Cancer Center.
The agreement to support “ADVENT-AML” Phase 1B trial Would involve the company’s CHM 0201, off-the-shelf universal donor NK cell therapy.
Under the trial, CHM 0201 will be tested in combination with standard of care therapy in newly diagnosed AML (acute myeloid leukaemia).
As per the terms of the agreement, CHM will provide CHM 0201 study drug and partial financial supportThe study will get support from several funding sources including Gateway for Cancer Research.
Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at MD Anderson, will lead the study.
More about the study
Under the ADVENT-AML study, up to 20 patients with newly diagnosed AML will be enrolled.
The enrolled subjects are not eligible for intensive chemotherapy or allogeneic stem cell transplantThe enrolment is expected to start by the end of this year at MD Anderson.
CHM highlighted that this study will be the first trial to assess the combination of CHM 0201 and the existing standard of care of Azacitidine with Venetoclax (AZA-VEN)
The trial had received IND clearance by the US FDA.
Details of AML
Data source: Company update